[{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Not Applicable"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"NF-?B","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Medtronic"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Corticosteroid","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Medtronic Plc \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Medtronic"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Medtronic Plc \/ Medtronic Plc"}]

Find Clinical Drug Pipeline Developments & Deals by Medtronic Plc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          May 09, 2024

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Arecor

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.

                          Brand Name : Propel

                          Molecule Type : Small molecule

                          Upfront Cash : $1,100.0 million

                          May 13, 2022

                          Lead Product(s) : Mometasone Furoate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Recipient : Intersect ENT

                          Deal Size : $1,100.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.

                          Brand Name : Propel

                          Molecule Type : Small molecule

                          Upfront Cash : $1,100.0 million

                          August 06, 2021

                          Lead Product(s) : Mometasone Furoate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Recipient : Intersect ENT

                          Deal Size : $1,100.0 million

                          Deal Type : Acquisition

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.

                          Brand Name : MiniMed 770G

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 01, 2020

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.

                          Brand Name : MiniMed 780G

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          June 12, 2020

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Blackstone Life Sciences

                          Deal Size : $337.0 million

                          Deal Type : Funding

                          blank